Please type a plus sign (+) inside this box -MAY 2 7 2003 tains a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to Substitute for form 1449A/PTO Compl t If Kn wri 09/944,954 Applicati n Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) September 1, 2001 Filing Date First Named Inventor Phillip M. Beart Group Art Unit 1014 1647 Examiner Name Wegen Attorney Docket Number SYM 116/118 Sheet

·		<del></del>	U.S. PATENT DOCUM	ENTS	
Examiner Initials*	Cite No.	US Patent Document  Number Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
172		5,658,782	Amara et al.	08-19-1997	
	_	5,731,348	Gu	03-24-1998	
		5,739,284	Hediger et al.	04-14-1998	
		5,776,774	Amara et al.	07-07-1998	
	5,840,516		Amara et al.	11-24-1998	
	5,882,926		Amara et al.	03-16-1999	-
		5,912,171	Amara et al.	06-15-1999	<b>-</b>
		5,919,699	Amara et al.	07-06-1999	-
		5,919,628	Amara et al.	07-06-1999	
	_	5,932,424	Amara et al.	08-03-1999	
		5,989,825	Amara et al.	11-23-1999	<u> </u>
		6,020,479	Amara et al.	02-01-2000	
	/	6,060,307	Amara et al.	05-09-2000	. <del>-</del>
		6,074,828	Amara et al.	06-13-2000	-
T.		6,090,560	Amara et al.	07-18-2000	<b>-</b>

Examiner Cit Initials' No			Foreign Patent Docur	nent	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>s</sup> (if known)	•		· igaico Appeal	
						1		
				1 1			<del> </del>	$\vdash$
		<del>  </del>		<del>                                     </del>	<del> </del>	<del> </del>	<u> </u>	+-
		$V^{-}$						
					<u> </u>	<u>l.                                    </u>		<u> </u>
xamine Signature		XPAN	rda M	land	Da	ate Considered 2	122/04	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or had citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent; Washington, DC 20231.

<sup>1</sup> Unique citation designation number 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Stind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant to place a check mark here if English language Translation is attached.

Į IĀÝ	2	8	2003
TECH CEI	VT	FR	i i enni!

		/
+	<i>  1</i>	
		f

	ilus sign (+) inside this b nwork Reduction Act of		s are required to respond	MAY 2 7 2000	st contains a valid OMB control number	Approved for use through 1031/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Olicer viol r up.	Substitute for			TRADEMARIE		omplete if Known
	STA	TEME	TION DISC NT BY AP		Application Number	09/944,954
		(000 00	2, 000.00.00.00		Filing Date	September 1, 2001
	-				First Named Inventor	Phillip M. Beart
					Group Art Unit	1814 \647
					Examiner Name	Negerx
Sheet	2	of	1	5	Attorney Docket Number	SYM 116/118
	<u> </u>				ENT DOOLINENTO	

			U.S. PATENT DOCUM	IENTS	<u> </u>
Examiner Cite Initials* No.		ite US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code (if know			
CLW		6,100,085	Arnara et al.	08-08-2000	
		ļ.,		<u> </u>	
		<u> </u>		<del></del>	· · · · · · · · · · · · · · · · · · ·
		<del> </del>			
		<del>                                     </del>			
		<b> </b>		-	-
	<u> </u>		<u> </u>		-
		<u> </u>			
i		1	1		

Examiner Initials*	Cite No. <sup>1</sup>			Foreign Patent Docu	ment	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	16
			Office.3	Number*	Kind Code <sup>5</sup> (if known)				
1.1	Ĺ.								
							· · · · · · · · · · · · · · · · · · ·	<del></del>	
		<b></b>		<b>_</b>		<u> </u>		↓	
		<del>[ ] </del>	L	<del></del>	•			<u>L</u> _	

\*EXAMINER: Initial if reference considered, whether not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

MEVER

MA 8 2003

Please type a plus sign (+) inside this box  $\rightarrow$ 

MAY 2 7 2003

ECH CENTER 1600/2900 PTC/SB/08A (10-96
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

,	Substitute for	form 1449A/PT	O TR.	4 DEMARKE	omplet if Kn wn
,	STATE		DISCLOSURE APPLICANT	Applicati n Number	09/944,954
	(	,	,,	Filing Date -	September 1, 2001
				First Named Inventor	Phillip M. Beart
				Group Art Unit	1614 \647
				Examiner Name	Degers
				Examine Name	1.7060013

xaminer's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	ΤT
Initials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
th.		APRICO, et al., "[3H]-(2S,4R)-4-methylglutamate: a novel ligand for the characterisation of astrocytic glutamate transporters," Soc. Neurol. Abstr. 26(1-2): 539.8 (2000), abstract only.	_
		ARRIZA, et al., "Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94(8): 4155-4160 (1997).	`
		ARRIZA, et al., "Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex," J. Neurosci. 14(9): 5559-5569 (1994).	-
		BERGLES & JAHR, "Glial contribution to glutamate uptake at Schaffer collateral commissural synapses in the hippocampus," J. Neurosci. 18(19): 7709-7716 (1998).	-
		BRIDGES, et al., "A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system," Curr. Pharmacout. Des. 5(5): 363-379 (1999).	-
	1	CARROLL, et al., "Regional distribution of low affinity kainate receptors in brain of Macaca fascicularis determined by autoradiography using [3H](2S,4R)-4-methylglutamate,* Neurosci. Lett. 255(2): 71-74 (1998).	_
	/	DUNLOP, et al., "The pharmacological profile of L-glutamate transport in human NT2 neurones is consistent with excitatory amino acid transporter 2," Eur. J. Pharmacol. 360(2-3): 249-256 (1998).	-
		DUNLOP, et al., "Properties of excitatory amino acid transport in the human U373 astrocytoma cell line," Brain Res. 839(2): 235-242 (1999).	
	1	FAIRMAN, et al., "An excitatory amino-acid transporter with properties of a ligand-gated chloride channel," Nature 375(6532): 599-603 (1995).	-
	1	FURUTA, et al., "Glutamate transporter protein subtypes are expressed differentially during rat CNS development," J. Neurosci. 17(21): 8363-8375 (1997).	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Signature

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box --

O 1 P & C 2 7 2003 & 3



PTC/SB08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

	Substitute for	form 1449A	PTO	Compl t if Kn wn				
	STATE	MENT	I DISCLOSURE BY APPLICANT outs as necessary)	Applicati n Number	09/944,954			
	, (use	as many sne	obis as riocessary)	Filing Date	September 1, 2001			
				First Named Inventor	Phillip M. Beart			
				Group Art Unit	1614 VWY			
				Examiner Name	Weacox			
Sheet	4	of	5	Attorney Docket Number	SYM 116/118			

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
2/1	)	GEGELASHVILI, et al., "High affinity glutamate transporters: regulation of expression and activity," Mol Pharmacol 52(1): 6-15 (1997).	_
	/	GU, et al., "Synthesis, resolution, and biological evaluation of the four stereoisomers of 4-methylglutamic acid: selective probes of kainate receptors," J Med Chem 38(14): 2518-2520 (1995).	_
	,	KANAI, et al., "Primary structure and functional characterization of a high-affinity glutamate transporter," Nature 360(6403): 467-471 (1992).	_
	1	LEBRUN, et al., "New beta-hydroxyaspartate derivates are competitive blockers for the bovine glutamate/aspartate transporter," J. Biol. Chem. 272(33): 20336-20339 (1997).	^
	1	LI, et al., "The Na*-dependent binding of [3H]L-aspartate in thaw-mounted sections of rat forebrain," Exp. Brain Res. 97(3): 415-422 (1994).	1
	l	LIPTON, et al., "Excitatory amino acids as a final common pathway for neurologic disorders," N. Engl. J. Med. 330(9): 613-622 (1994).	-
	/	MITROVIC, et al., "Identification of functional domains of the human glutamate transporters EAAT1 and EAAT2," J. Biol. Chem. 273(24): 14698-14706 (1998).	_
		PALOS, et al., "Rat C6 and human astrocytic tumor cells express a neuronal type of glutamate transporter," Brain Res. Mol. Brain Res. 37(1-2): 297-303 (1996).	
	/	PINES, et al., *Cloning and expression of a rat brain L-glutamate transporter,* Nature 360(6403): 464-467 (1992).	
	/	ROBINSON, et al., *Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system,* Adv. Pharmacol 37: 69-115 (1997).	-
Examiner's	Т	Date Considered 2/22/24	
Signature		TANON MOVO	

\*EXAMINÉR: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

•	olus sign (+) inside Uris bo * einvork Reduction Act of 1		are required to respond to a collection of in	MAY 2 7 2000 S	PTO'SBOBA (10-95 PECH CENTER 1 And Approved for use through 10/31/39. OMB 0651/0031 PECH CENTER 1 And Approved for use through 10/31/39. OMB 0651/0031 OMB 0651/0031 OMB 0651/0031 OMB 0651/0031 OMB 0651/0031 OMB 0651/0031
	Substitute for f				Complet If Known
	STATE	WENT	N DISCLOSURE BY APPLICANT neets as necessary)	Applicati n Number	09/944,954
1	`	,	•	Filing Date	September 1, 2001
				First Named Inventor	Phillip M. Beart
				Group Art Unit	1614 \bU7
				Examiner Name	niege /x
Sheet	5	of	5	Attorney Docket Number	SYM 116/118

OTHER ART NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
The state of the s	-	ROTHSTEIN, et al., "Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate," Neuron 16(3): 675-686 (1996).	4
	/	SHIMAMOTO, et al., "DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters," Mol. Pharmacol. 53(2): 195-201 (1998).	-
	1	STORCK, et al., "Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain," <i>Proc. Natl. Sci. U.S.A.</i> 89(22): 10955-10959 (1992).	
	1	TOMS, et al., 'A novel kainate receptor ligand [3H]-(2S,4R)-4-methylglutamate: pharmacological characterization in rabbit brain membranes,' Neuropharmacology 36(11-12): 1483-1488 (1997).	-
	/	VANDENBERG, "Molecular pharmacology and physiology of glutamate transporters in the central nervous system," Clin. Exp. Pharmacol. Physiol. 25(6): 393-400 (1998).	-
	/	VANDENBERG, et al., "Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2," Mol. Pharmacol. 51(5): 809-815 (1997).	T.
	<b>人</b>	VANDENBERG, et al., "Serine-O-sulphate transport by the human glutamate transporter, EAAT2," Br. J. Pharmacol. 123(8): 1593-1600 (1998).	-
	/	YE, et al., *Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange,* J. Neurosci. 19(24): 10767-10777 (1999).	-
	/	ZHOU, et al., "(2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors" J. Pharmacology Exper. Therapeutics 280(1): 422-427 (1997).	-
		N	

\*EXAMINER: Initial if reference considered, whether or notal tation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Signature

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents, <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.